CG Oncology, Inc.CGONEarnings & Financial Report
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
Revenue
$1.7M
Gross Profit
N/A
Operating Profit
$-51.1M
Net Profit
$-43.8M
Gross Margin
N/A
Operating Margin
-3069.0%
Net Margin
-2629.5%
YoY Growth
3774.4%
EPS
$-0.57
CG Oncology, Inc. Q3 FY2025 Financial Summary
CG Oncology, Inc. reported revenue of $1.7M (up 3774.4% YoY) for Q3 FY2025, with a net profit of $-43.8M (down 114.7% YoY) (-2629.5% margin).
Key Financial Metrics
| Total Revenue | $1.7M |
|---|---|
| Net Profit | $-43.8M |
| Gross Margin | N/A |
| Operating Margin | -3069.0% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
CG Oncology, Inc. Q3 FY2025 revenue of $1.7M breaks down across 2 segments, led by Commercial And Development Revenue at $1.5M (90.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Commercial And Development Revenue | $1.5M | 90.5% |
| Other | $158.0K | 9.5% |
CG Oncology, Inc. Quarterly Revenue & Net Profit History
CG Oncology, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.3M | +409.2% | $-41.3M | -1779.0% |
| Q3 FY2025 | $1.7M | +3774.4% | $-43.8M | -2629.5% |
| Q2 FY2025 | $0 | — | $-41.4M | N/A |
| Q4 FY2024 | $456.0K | +45500.0% | $-31.8M | -6973.7% |
| Q1 FY2024 | $529.0K | +172.7% | $-16.9M | -3200.8% |
Income Statement
| Q1 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Revenue | $529000 | $456000 | $0 | $1.7M | $2.3M |
| YoY Growth | 172.7% | 45500.0% | N/A | 3774.4% | 409.2% |
Balance Sheet
| Q1 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Assets | $579.1M | $754.8M | $701.4M | $729.9M | $791.6M |
| Liabilities | $10.2M | $21.4M | $31.1M | $42.3M | $39.0M |
| Equity | $568.9M | $733.4M | $670.4M | $687.6M | $752.6M |
Cash Flow
| Q1 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-26.0M | $-20.7M | $-28.0M | $-38.9M | $-36.2M |